02 July 2026
02 July 2026
Our editorial team delve into the key takeaways from the 2026 HLTH Europe conference and the 2026 BIO International Convention.
The lead product on AlzeCure’s platform has already demonstrated positive Phase I results.
Children as young as two with either sickle cell disease or thalassemia are now eligible for the gene therapy.
The real-world data study tracked Parkinson's disease patients for 12 months during treatment with AbbVie's Vyalev
Divarasib outperformed existing therapies in patients with KRAS G12C non-small cell lung cancer (NSCLC).
Namodenoson showed a tolerable safety profile consistent with previous studies.
Additional data on fall reduction could help give NeuroDerm's Onerji a competitive edge.
Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
